#53. The Math of AI Drug Discovery

Is AI drug discovery finally becoming investable, not just imaginable? In this episode, we unpack the blockbuster alliance between Insilico Medicine and Eli Lilly, including the eye-catching $115 million upfront payment and the broader $2.75 billion deal that is pushing investors to rethink how AI creates value in biopharma. We break down the financial logic behind the story, from the clinical “Valley of Death” to risk-adjusted net present value, and explore why business model matters as much as scientific promise. Along the way, we examine Insilico’s hybrid strategy of both enabling discovery for partners and advancing its own pipeline, a model that blends software, biotech, and pharma economics. The result is a bigger question: in one of the world’s highest-failure industries, what does it take for an AI company to earn real credibility? This episode explores how the boundaries between tech and pharma are starting to shift, and what that could mean for the future of medicine. Produced by Dr. Jake Chen.